Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617

被引：0
|
作者：
Ferdinandus, Justin [3 ]
Eppard, Elisabeth [2 ]
Kuerpig, Stefan [3 ]
Gaertner, Florian [1 ]
Fimmers, Rolf [3 ]
Hauser, Stefan [3 ]
Essler, Markus [3 ]
Ahmadzadehfar, Hojjat [3 ]
机构：
[1] Univ Klinikum Bonn, Bonn, Germany
[2] Univ Hosp, Bonn, Germany
[3] Univ Hosp Bonn, Nucl Med, Bonn, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1432
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, J.
    Eppard, E.
    Kuerpig, S.
    Gaertner, F.
    Fimmers, R.
    Yordanova, A.
    Hauser, S.
    Essler, M.
    Feldmann, G.
    Ahmadzadehfar, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S212 - S213
  • [2] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [3] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [4] Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Becker, Anja
    Eppard, Elisabeth
    Kuerpig, Stefan
    Fisang, Christian
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [5] Salivary gland dosimetry in therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Baumgarten, J.
    Groener, D.
    Gruenwald, F.
    Sabet, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S102 - S102
  • [6] EVALUATION OF RESPONSE TO 177LU-PSMA-617 BY SITE SPECIFIC DISEASE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
    Mahmoud, Ahmed M.
    Ahmed, Mohamed E.
    Abdelrazek, Ahmad
    Childs, Daniel
    Kendi, Ayse T.
    Johnson, Geoffrey
    Karnes, Jeffrey
    Kwon, Eugene
    Andrews, Jack
    [J]. JOURNAL OF UROLOGY, 2024, 211 (05): : E1004 - E1004
  • [7] Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis
    Kim, Yong Joong
    Kim, Yong-il
    [J]. CLINICAL NUCLEAR MEDICINE, 2018, 43 (10) : 728 - 734
  • [8] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Rami, Avina
    Ng, Thomas S. C.
    Rothmann, Emily
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Choudhury, Atish Dipankar
    Gao, Xin
    Haberman, Veronica
    Kako, Bashar
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    O'Shea, Aileen
    Taplin, Mary-Ellen
    Jacene, Heather
    Ravi, Praful
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
  • [9] Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
    Ahmadzadehfar, Hojjat
    Eppard, Elisabeth
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Schlenkhoff, Carl Diedrich
    Gaertner, Florian
    Rogenhofer, Sebastian
    Essler, Markus
    [J]. ONCOTARGET, 2016, 7 (11) : 12477 - 12488
  • [10] Increased PSMA Expression in 177Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide A Potential Game-Changer
    Aggarwal, Piyush
    Kaur, Komalpreet
    Sood, Ashwani
    Periasamy, Kannan
    Nagi, Shreya
    Mittal, Bhagwant Rai
    [J]. CLINICAL NUCLEAR MEDICINE, 2023, 48 (05) : 411 - 413
12345